



The Bladder. *Int Neurourol J*, 2017; 21: 6. <https://www.ncbi.nlm.nih.gov/pubmed/28361520>.

35. Liao CH, et al. Mirabegron 25mg Monotherapy Is Safe but Less Effective in Male Patients With Overactive Bladder and Bladder Outlet Obstruction. *Urology* 2018; 117: 115. <https://www.ncbi.nlm.nih.gov/pubmed/29630956>.

36. Van Gelderen M, et al. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middleagedm to elderly men. *International Journal of Clinical Pharmacology and Therapeutics* 2014; 52: 693. <https://www.ncbi.nlm.nih.gov/pubmed/24755125>.

37. Athanasopoulos A, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. *J Urol* 2003; 169: 2253. <https://www.ncbi.nlm.nih.gov/pubmed/12771763>.

38. Roehrborn CG, et al. Efficacy and safety of a fixed-dose combination of dutasteride And tamsulosin treatment (Duodart((R))) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naive men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. *BJU Int* 2015; 116: 450. <https://www.ncbi.nlm.nih.gov/pubmed/25565364>.

39. Roehrborn CG, et al. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy In patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of The CombAT study. *BJU Int* 2014; 113: 623. <https://www.ncbi.nlm.nih.gov/pubmed/24127818>.

40. Kaplan SA, et al. Time Course of Incident Adverse Experiences Associated with Doxazosin, Finasteride and Combination Therapy in Men with Benign Prostatic Hyperplasia: The MTOPS Trial. *J Urol* 2016; 195: 1825. <https://www.ncbi.nlm.nih.gov/pubmed/26678956>.

41. Lee HN, et al. Rate and associated factors of solifenacin add-on after tamsulosin Monotherapy in men with voiding and storage lower urinary tract symptoms. *International Journal of Clinical Practice* 2015; 69: 444. <https://www.ncbi.nlm.nih.gov/pubmed/25363606>.

42. Van Kerrebroeck P, et al. Combination therapy with solifenacin and tamsulosin oral Controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. *Eur Urol* 2013; 64: 1003. <https://www.ncbi.nlm.nih.gov/pubmed/23932438>.

43. Athanasopoulos A, et al. The role of antimuscarinics in the management of men with Symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. *Eur Urol* 2011; 60: 94. <https://www.ncbi.nlm.nih.gov/pubmed/21497434>.

44. Kaplan SA, et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. *Int J Clin Pract* 2011; 65: 487. <https://www.ncbi.nlm.nih.gov/pubmed/21210910>.

45. Kim HJ, et al. Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker With an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis. *PLoS One* 2017; 12: e0169248. <https://www.ncbi.nlm.nih.gov/pubmed/28072862>.

46. Drake MJ, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: Results from the NEPTUNE study and NEPTUNE II open-label extension. *Eur Urol* 2015. 67: 262. <https://www.ncbi.nlm.nih.gov/pubmed/25070148>.

47. Drake MJ, et al. Responder and health-related quality of life analyses in men with Lower Urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin OCAS: results from the NEPTUNE study. *BJU Int* 2016; 117: 165. <https://www.ncbi.nlm.nih.gov/pubmed/25907003>.

48. Gong M, et al. Tamsulosin combined with solifenacin versus tamsulosin monotherapy for male lower urinary tract symptoms: a meta-analysis. *Curr Med Res Opin* 2015; 31: 1781. <https://www.ncbi.nlm.nih.gov/pubmed/26211817>.

49. Kaplan SA, et al. Solifenacin plus tamsulosin combination treatment in men with lower urinary Tract symptoms and bladder outlet obstruction: a randomized controlled trial. *Eur Urol* 2013. 63: 158. <https://www.ncbi.nlm.nih.gov/pubmed/22831853>.

50. Stárka L, Sosvorová L, Mikšátková P. Herbální přípravky používané při léčbě příznaků benigní hyperplazie prostaty. *Urol. praxi* 2012; 13(6): 244–246.

51. Madersbacher S, et al. Plant extracts: sense or nonsense? *Curr Opin Urol* 2008; 18: 16. <https://www.ncbi.nlm.nih.gov/pubmed/18090484>.

52. Kliment J, Horňák M, et al. Preparáty z rastlinných extraktov, In: Kliment J, Horňák M, et al. Benígna hyperplázia prostaty. Osveta, Martin 1996: 167–170. ISBN: 80-217-0343-1.

53. De Monte C, et al. Modern extraction techniques and their impact on the pharmacological profile of *Serenoa repens* extracts for the treatment of lower urinary tract symptoms. *BMC Urol* 2014; 14: 63. <https://www.ncbi.nlm.nih.gov/pubmed/25112532>.

54. Slíva J. *Serenoa repens* v léčbě benigní hyperplazie prostaty. *Urol. praxi* 2017; 18(4): 165–168.

55. Vávřová L. Účinky hexanového extraktu z palmy pilovité (*Serenoa repens*, Permixon® 160 mg, v ČR dostupný pod názvem Capistan®) na zánětlivé biomarkery v léčbě obtíží souvisejících s benigní hyperplazií prostaty. *Urol. praxi* 2016; 17(4): 192–194.

56. European Medicines Agency Committee on Herbal Medicinal Products. European Union Herbal monograph on *Serenoa repens* (W. Bartram) Small, fructus. EMA/HMPC/280079/2013, 2015. https://www.ema.europa.eu/en/documents/herbal-monograph/draft-european-union-herbalmonograph-serenoa-repens-w-bartram-small-fructus_en.pdf.